Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tralokinumab + TCS in Moderate-to-Severe Atopic Dermatitis (ECZTRA 3)
NCT03363854Phase 3Completed
- Sponsor
- LEO Pharma
- Start
- Feb 2018
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of tralokinumab in atopic dermatitis (AD) (5 arms), sponsored by LEO Pharma. Primary endpoints: Investigator's Global Assessment Score of 0 (Clear) or 1 (Almost Clear) at 16 weeks and 75% Reduction in Eczema Area and Severity Index at 16 weeks. Started Feb 2018; status: completed.
02
Drugs
tralokinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03363854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03363854.